Jan T Kielstein
Overview
Explore the profile of Jan T Kielstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
253
Citations
4624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lehmann K, Reubke B, Wanninger R, Lindgren M, Glowka T, Kielstein J, et al.
Clin Kidney J
. 2025 Feb;
18(2):sfae403.
PMID: 39968508
Indications for peritoneal dialysis (PD) have undergone a paradigm shift in recent years. Medical barriers previously viewed as contraindications for PD such as anuria, autosomal dominant polycystic kidney disease, cardiovascular...
2.
Gienapp A, Borchina D, Engel C, Hossain M, Kielstein J
Ther Apher Dial
. 2024 Dec;
29(2):325-326.
PMID: 39659193
No abstract available.
3.
Okioma R, Soki K, Hay A, Kielstein J
Case Rep Nephrol Dial
. 2024 Oct;
14(1):171-177.
PMID: 39474253
Introduction: The Seraph 100 Microbind Affinity Filter is a biomimetic adsorbent device that can remove pathogens from the blood. Case Presentation: Here, we report the successful use of the Seraph...
4.
Seffer M, Kielstein J
Med Klin Intensivmed Notfmed
. 2024 Jul;
PMID: 38981926
Background: In 2019 the World Health Organization (WHO) listed antimicrobial resistance among the top 10 threats to global health. The Seraph® 100 Microbind® Affinity blood filter (Seraph® 100) has been...
5.
Schmieszek J, Fuehner T, Renger I, Welte T, Menne J, Fuge J, et al.
Ther Apher Dial
. 2024 May;
28(5):802-809.
PMID: 38736311
Introduction: The Seraph 100 Microbind Affinity blood filter eliminate bacteria, viruses, fungi and toxins from blood stream. Methods: This is a prospective multicenter observational biomarker trial in PCR-positive SARS-CoV-2 patients...
6.
Stoneman S, Balmer F, Moore L, Fontana M, Kielstein J, Woywodt A
Clin Kidney J
. 2024 May;
17(5):sfae062.
PMID: 38699480
No abstract available.
7.
Steinbrenner I, Kotsis F, Kosch R, Meiselbach H, Barthlein B, Stockmann H, et al.
Nephrol Dial Transplant
. 2024 Apr;
39(12):2016-2024.
PMID: 38664006
Background: Persons with chronic kidney disease (CKD) are at increased risk of adverse events, early mortality and multimorbidity. A detailed overview of adverse event types and rates from a large...
8.
Seffer M, Meyer T, Borchina D, Kielstein J, Schmidt J
J Vasc Access
. 2024 Feb;
26(2):596-600.
PMID: 38415617
Introduction: The Seraph® 100 Microbind® Affinity blood filter (Seraph® 100) has been in use since 2019 for the treatment of fulminant or difficult to treat blood stream infections as an...
9.
Ruhe J, Nadal J, Barthlein B, Meiselbach H, Schultheiss U, Kotsis F, et al.
Clin Kidney J
. 2023 Nov;
16(11):2032-2040.
PMID: 37915914
Background: Diabetes mellitus (DM) and chronic kidney disease (CKD) are well-known cardiovascular and mortality risk factors. To what extent they act in an additive manner and whether the etiology of...
10.
Luck C, Beutel G, Kuhn-Velten W, Kielstein J
Case Rep Nephrol Dial
. 2023 Jul;
13(1):70-74.
PMID: 37484798
The largest study on cyclophosphamide pharmacokinetics in dialysis patients comprises of 6 subjects. In the 2 decades since these data were obtained, dialyser membranes, treatment intensities, and treatment duration have...